ES2139598T3 - Procedimientos para la produccion de miembros de parejas de union especifica. - Google Patents

Procedimientos para la produccion de miembros de parejas de union especifica.

Info

Publication number
ES2139598T3
ES2139598T3 ES92910174T ES92910174T ES2139598T3 ES 2139598 T3 ES2139598 T3 ES 2139598T3 ES 92910174 T ES92910174 T ES 92910174T ES 92910174 T ES92910174 T ES 92910174T ES 2139598 T3 ES2139598 T3 ES 2139598T3
Authority
ES
Spain
Prior art keywords
rgdp
sbp
members
production
polypeptide chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910174T
Other languages
English (en)
Inventor
Gregory Paul Winter
Kevin Stuart Johnson
Andrew David Griffiths
Andrew John Hammond Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
MedImmune Ltd
Original Assignee
Medical Research Council
Cambridge Antibody Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909015198A external-priority patent/GB9015198D0/en
Priority claimed from GB909024503A external-priority patent/GB9024503D0/en
Priority claimed from GB919104744A external-priority patent/GB9104744D0/en
Priority claimed from GB919110549A external-priority patent/GB9110549D0/en
Priority claimed from GB929206318A external-priority patent/GB9206318D0/en
Application filed by Medical Research Council, Cambridge Antibody Technology Ltd filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2139598T3 publication Critical patent/ES2139598T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Package Frames And Binding Bands (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LA INVENCION SE REFIERE A METODOS Y KITS PARA PRODUCIR PARES DE ENLACE ESPECIFICO (SBP). LAS POBLACIONES DE COMPONENTES DE CADENA DE POLIPEPTIDOS DE ELEMENTOS SBP SE COMBINAN PARA FORMAR LIBRERIAS DE SBPS MOSTRADOS POR PAQUETES DE INDICACION GENETICA DUPLICABLE SEGREGADA (RGDP). AL MENOS UNA DE LAS CADENAS DE POLIPEPTIDOS SE EXPRESA COMO UNA FUSION CON UN COMPONENTE DE UN RGDP QUE MUESTRA ESTA CADENA DE POLIPEPTIDOS EN LA SUPERFICIE DE RGDP. AL MENOS UNA POBLACION DE CADENAS DE POLIPEPTIDOS SE EXPRESA A PARTIR DE ACIDO NUCLEIDO QUE ES CAPAZ DE FORMAR UN PAQUETE UTILIZANDO UN COMPONENTE DE UN RGDP, CON LO CUAL EL MATERIAL GENETICO DE RGDP PRODUCIDO CODIFICA UNA CADENA DE POLIPEPTIDOS. EL METODO PERMITE LA PRODUCCION DE LIBRERIAS DE ELEMENTOS SBP MULTIMERICOS DE UN NUMERO MUY AMPLIO DE POSIBLES COMBINACIONES. EN UNA REALIZACION DE LA INVENCION UN METODO EMPLEA "UNA MEZCLA DE CADENAS" EN LA PRODUCCION DE ELEMENTOS SBP DE ESPECIFICIDAD DESEADA PARA UN ELEMENTO SBP DUPLICADA. LOS PROCEDIMIENTOSDE SELECCION TAMBIEN SE DESCRIBEN.
ES92910174T 1990-07-10 1992-05-15 Procedimientos para la produccion de miembros de parejas de union especifica. Expired - Lifetime ES2139598T3 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB909015198A GB9015198D0 (en) 1990-07-10 1990-07-10 Binding substance
GB909022845A GB9022845D0 (en) 1990-07-10 1990-10-19 Antibodies
GB909024503A GB9024503D0 (en) 1990-11-12 1990-11-12 Binding substances
GB919104744A GB9104744D0 (en) 1991-03-06 1991-03-06 Binding substances
GB919110549A GB9110549D0 (en) 1991-05-15 1991-05-15 Binding substances
PCT/GB1991/001134 WO1992001047A1 (en) 1990-07-10 1991-07-10 Methods for producing members of specific binding pairs
GB929206318A GB9206318D0 (en) 1992-03-24 1992-03-24 Binding substances
PCT/GB1992/000883 WO1992020791A1 (en) 1990-07-10 1992-05-15 Methods for producing members of specific binding pairs

Publications (1)

Publication Number Publication Date
ES2139598T3 true ES2139598T3 (es) 2000-02-16

Family

ID=27547091

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910174T Expired - Lifetime ES2139598T3 (es) 1990-07-10 1992-05-15 Procedimientos para la produccion de miembros de parejas de union especifica.

Country Status (9)

Country Link
EP (1) EP0585287B1 (es)
JP (1) JPH06508511A (es)
AT (1) ATE185601T1 (es)
AU (1) AU665190B2 (es)
CA (1) CA2109602C (es)
DK (1) DK0585287T3 (es)
ES (1) ES2139598T3 (es)
GR (1) GR3032186T3 (es)
WO (1) WO1992020791A1 (es)

Families Citing this family (1068)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) * 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
DE69233408T2 (de) * 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP1696031B1 (en) * 1991-12-02 2010-04-07 MedImmune Limited Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0656941B1 (en) * 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9313509D0 (en) * 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
FR2715940B1 (fr) * 1994-02-10 1996-04-26 Pasteur Merieux Serums Vacc Procédé de préparation d'une banque multicombinatoire de vecteurs d'expression de gènes d'anticorps, banque et systèmes d'expression d'anticorps "coliclonaux" obtenus.
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US6143557A (en) 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
EP0937098B1 (en) 1995-06-07 2002-08-14 Invitrogen Corporation Recombinational cloning in vitro using engineered recombination sites
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
NZ311174A (en) 1995-06-30 1999-04-29 Mochida Pharm Co Ltd Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
FR2741892B1 (fr) * 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
US6538114B1 (en) 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
EP0985033A4 (en) * 1997-04-04 2005-07-13 Biosite Inc POLYVALENT AND POLYCLONAL LIBRARIES
DE69842225D1 (de) 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
WO1999006587A2 (en) * 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6723512B2 (en) * 1997-08-29 2004-04-20 Selective Genetics Inc. Methods using genetic package display for detecting and identifying protein-protein interactions that facilitate internalization and transgene expression and cells or tissues competent for the same and methods for evolving gene delivery vectors
CA2302292A1 (en) 1997-08-29 1999-03-04 Selective Genetics, Inc. Methods using phage display for selecting internalizing ligands for gene delivery
US6589730B1 (en) 1997-08-29 2003-07-08 Selective Genetics, Inc. Methods for identifying protein-protein interactions by selective transduction
US6451527B1 (en) * 1997-08-29 2002-09-17 Selective Genetics, Inc. Methods using genetic package display for selecting internalizing ligands for gene delivery
GB9718455D0 (en) 1997-09-02 1997-11-05 Mcgregor Duncan P Chimeric binding peptide library screening method
DE69836092T2 (de) 1997-10-24 2007-05-10 Invitrogen Corp., Carlsbad Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
US7351578B2 (en) 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
ATE393912T1 (de) 1998-02-04 2008-05-15 Invitrogen Corp Microarrays und ihre verwendungen
US7056517B2 (en) 1998-04-13 2006-06-06 The Forsyth Institute Glucosyltransferase immunogens
US7163682B2 (en) 1998-04-13 2007-01-16 The Forsyth Institute Glucan binding protein and glucosyltransferase immunogens
ES2299244T3 (es) * 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
PT1086138E (pt) 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
US6368793B1 (en) 1998-10-14 2002-04-09 Microgenomics, Inc. Metabolic selection methods
US6420110B1 (en) * 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
DE60042969D1 (de) 1999-03-02 2009-10-29 Life Technologies Corp Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
BR0009323A (pt) 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2377573A1 (en) * 1999-06-26 2001-01-04 Joelle Nina Pelletier An in vivo library-versus-library selection of optimized protein-protein interactions
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
KR20020025990A (ko) 1999-08-23 2002-04-04 나가야마 오사무 에이치엠1.24 항원의 발현 증강제
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
ATE391789T1 (de) 1999-12-10 2008-04-15 Invitrogen Corp Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen
EP1626056B1 (en) 1999-12-30 2012-03-28 President and Fellows of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1280923A2 (en) 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
EP1714661A3 (en) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US7244560B2 (en) 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
DE60112282T2 (de) 2000-05-22 2006-04-20 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Auf rezeptorgrundlage arbeitende screening-verfahren für protein wechselwirkungen
DE60141463D1 (de) 2000-06-08 2010-04-15 Immune Disease Inst Inc Methoden und verbindungen zur hemmung immunoglobulin-vermittelter reperfusions-verletzungen
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
EP1301532B1 (en) 2000-07-14 2011-02-02 CropDesign N.V. Plant cyclin-dependent kinase inhibitors
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002046208A2 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
JP2004526425A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
NZ526617A (en) 2000-11-28 2004-09-24 Wyeth Corp Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
EP1377664A2 (en) 2001-02-23 2004-01-07 DSM IP Assets B.V. Genes encoding proteolytic enzymes from aspargilli
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
NZ528250A (en) 2001-03-07 2006-09-29 Childrens Medical Center Method to screen peptide display libraries using minicell display
WO2003004643A2 (en) 2001-07-03 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Reversed mammalian protein-protein interaction trap
US7795494B2 (en) 2001-03-22 2010-09-14 Abbott Laboratories Transgenic mice expressing antibodies specific for genes of interest and uses thereof
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
AU2002322388A1 (en) 2001-06-22 2003-01-08 E.I. Du Pont De Nemours And Company Defensin polynucleotides and methods of use
JP4351043B2 (ja) 2001-07-09 2009-10-28 エラン ファーマシューティカルズ，インコーポレイテッド アミロイド毒性の阻害方法
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003051917A2 (en) 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
WO2003068819A1 (en) 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
EP1572149A2 (en) 2002-03-07 2005-09-14 The Forsyth Institute Immunogenicity of glucan binding protein
US7745192B2 (en) 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CN101684470A (zh) 2002-05-21 2010-03-31 Dsmip资产有限公司 新的磷脂酶及其用途
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2490804C (en) 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DE60335383D1 (de) 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20040131614A1 (en) 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
ATE469913T1 (de) 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
CN1675355A (zh) 2002-08-19 2005-09-28 帝斯曼知识产权资产管理有限公司 新颖的脂肪酶及其用途
EP2311980A1 (en) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US7455989B2 (en) 2002-08-20 2008-11-25 Yeda Research And Development Co. Ltd. AKAP84 and its use for visualization of biological structures
WO2004019966A1 (ja) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液製剤の安定化方法
CA2496508C (en) 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20040248323A1 (en) 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
EP1642971B1 (en) 2003-06-18 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
FR2859725B1 (fr) 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
WO2005034732A2 (en) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2005035548A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
EP2444805A3 (en) 2004-01-21 2012-06-20 Fujirebio America, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
CA2560066A1 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research, Inc. Natural igm antibodies and inhibitors thereof
WO2005095964A2 (en) 2004-03-24 2005-10-13 Tripath Imaging, Inc. Methods and compositions for the detection of cervical disease
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
EP1766014A4 (en) 2004-06-03 2008-12-10 Athlomics Pty Ltd AGENTS AND METHODS FOR THE DIAGNOSIS OF STRESS
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
CN101014365B (zh) 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
JP5014130B2 (ja) 2004-08-02 2012-08-29 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AU2006226192A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
US7595380B2 (en) 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
WO2006130374A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
WO2007094842A2 (en) 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
CN103145837A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
CN101501215A (zh) 2005-07-07 2009-08-05 阿什洛米克斯控股有限公司 用于诊断内毒素血症的多核苷酸标记基因及它们的表达
DK1915620T3 (da) 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SI2447283T1 (sl) 2005-09-07 2015-12-31 Amgen Fremont Inc. Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007055378A1 (ja) 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
ATE547709T1 (de) 2005-11-14 2012-03-15 Metamol Theranostics Llc Tumorinvasionsfördernde peptidsequenz
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CA2631615A1 (en) 2005-11-30 2007-04-24 Massachusetts Institute Of Technology Pathogen detection biosensor
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
JP4976412B2 (ja) 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
JP2009524438A (ja) 2006-01-27 2009-07-02 トライパス イメージング インコーポレイテッド 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
NZ569988A (en) 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666478A3 (en) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Uses and compositions for treatment of psoriasis
JP5242382B2 (ja) 2006-04-14 2013-07-24 株式会社医学生物学研究所 エフェクター機能を有するポリペプチド変異体
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
ES2544888T3 (es) 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
ES2372709T3 (es) 2006-07-05 2012-01-25 Catalyst Biosciences, Inc. Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
WO2008007755A1 (en) 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2047862B9 (en) 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
KR20090058512A (ko) 2006-08-04 2009-06-09 아스트라제네카 아베 Ｅｒｂｂ2에 대한 인간 항체
EP2548576B1 (en) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnosis of cancer using anti-desmoglein-3 antibodies
HUE052220T2 (hu) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
KR20090069330A (ko) 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
AU2007311946A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP2514439A1 (en) 2006-11-15 2012-10-24 Functional Genetics, Inc. Anti-TSG101antibodies and their uses for treatment of viral infections
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
BRPI0720116B8 (pt) 2006-12-05 2021-07-27 Decode Genetics Ehf método para determinar uma suscetibilidade à arritmia cardíaca ou acidente vascular cerebral em um indivíduo humano, uso de uma sonda de oligonucleotídeo, e, aparelho para determinar um indicador genético para a arritmia cardíaca e/ou acidente vascular cerebral em um indivíduo humano
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2586458B1 (en) 2006-12-27 2016-08-24 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
EP2522743A3 (en) 2007-02-07 2013-08-07 Decode Genetics EHF. Genetic variants contributing to risk of prostate cancer
DK2471954T3 (en) 2007-02-21 2016-09-12 Decode Genetics Ehf Susceptibility genetic variants associated with cardiovascular diseases
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
LT3067066T (lt) 2007-02-23 2019-06-25 Prothena Biosciences Limited Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
AU2008219972A1 (en) 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
RU2571931C2 (ru) 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2535425A1 (en) 2007-05-25 2012-12-19 Decode Genetics EHF. Variantes génétiques sur les chr 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
WO2008151819A2 (en) 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
CN101784564B (zh) 2007-07-13 2014-07-02 约翰霍普金斯大学 B7-dc变体
EP2174667B1 (en) 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
BRPI0817482B8 (pt) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
CN108130327A (zh) 2007-10-11 2018-06-08 第三共株式会社 靶向破骨细胞相关蛋白Siglec-15的抗体
PL2202307T5 (pl) 2007-10-15 2021-10-04 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania przeciwciała
EP2230300A4 (en) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
CN104109208A (zh) 2007-11-14 2014-10-22 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
CN101918452A (zh) 2007-11-15 2010-12-15 中外制药株式会社 与Anexelekto结合的单克隆抗体及其利用
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
AU2009203464A1 (en) 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
CA2714521A1 (en) 2008-02-14 2009-08-20 Decode Genetics Ehf Susceptibility variants for lung cancer
EP2271366A4 (en) 2008-02-28 2012-06-20 3M Innovative Properties Co ANTIBODIES DIFFICULT CLOSTRIDIUM SPORES AND USES THEREOF
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
NZ588905A (en) 2008-04-01 2012-08-31 Decode Genetics Ehf Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
CN102089430B (zh) 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
WO2009147695A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
KR20110038047A (ko) 2008-06-20 2011-04-13 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 산화 ＬＤＬ／β２ＧＰＩ복합체에 대한 항체 및 그 용도
CA2729934A1 (en) 2008-07-07 2010-01-14 Decode Genetics Ehf Genetic variants for breast cancer risk assessment
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
KR20110040886A (ko) 2008-07-08 2011-04-20 아보트 러보러터리즈 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
EP3199630B1 (en) 2008-09-05 2019-05-08 President and Fellows of Harvard College Continuous directed evolution of proteins and nucleic acids
US20110287026A1 (en) 2008-09-23 2011-11-24 President And Fellows Of Harvard College Sirt4 and uses thereof
WO2010039533A2 (en) 2008-09-23 2010-04-08 Wyeth Methods for predicting production of activating signals by cross-linked binding proteins
JP2012503982A (ja) 2008-09-26 2012-02-16 ワイス・エルエルシー 適合性ディスプレイベクター系
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
JP2012505900A (ja) 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
ES2732504T3 (es) 2008-10-29 2019-11-22 Circular Commitment Company Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
CN105646643A (zh) 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
RU2481824C2 (ru) 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
AU2009319772A1 (en) 2008-11-26 2010-06-03 Centocor Research & Development, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2
MX2011005691A (es) 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
CA2748990A1 (en) 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US20100227335A1 (en) 2009-03-05 2010-09-09 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
WO2010102177A1 (en) 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2414543B1 (en) 2009-04-03 2016-10-12 Decode Genetics EHF Genetic markers for risk management of atrial fibrillation and stroke
EP2377932B1 (en) 2009-04-09 2020-11-18 Daiichi Sankyo Company, Limited ANTI-Siglec-15 ANTIBODY
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
ES2725356T3 (es) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
AU2010242972B2 (en) 2009-04-29 2015-07-09 Abbvie Biotechnology Ltd Automatic injection device
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
EP2270053A1 (en) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
EP2261242A1 (en) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP2272979A1 (en) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Method for testing a subject thought to be predisposed to having cancer
CA2766861A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
US8796182B2 (en) 2009-07-10 2014-08-05 Decode Genetics Ehf. Genetic markers associated with risk of diabetes mellitus
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
CN102596220A (zh) 2009-07-31 2012-07-18 韦恩州立大学 单磷酸化的脂质a衍生物
US9259476B2 (en) 2009-07-31 2016-02-16 Wayne State University Monophosphorylated lipid A derivatives
US20120282173A1 (en) 2009-08-17 2012-11-08 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP2473523A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ599100A (en) 2009-10-20 2014-07-25 Abbvie Inc Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
EP2499491B1 (en) 2009-11-11 2015-04-01 Gentian AS Immunoassay for assessing related analytes of different origin
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
US8685524B2 (en) 2010-01-29 2014-04-01 Toray Industries, Inc. Polylactic acid-based resin sheet
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
US9228171B2 (en) 2010-02-05 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulatory B cells (tBREGS) and their use
NO2535358T3 (es) 2010-02-10 2018-05-19
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
TWI500427B (zh) 2010-05-14 2015-09-21 Abbvie Inc Ｉｌ－１結合蛋白
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
MX2012014080A (es) 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
WO2012047324A2 (en) 2010-06-10 2012-04-12 President And Fellows Of Harvard College Systems and methods for amplification and phage display
BR112012032206A2 (pt) 2010-06-16 2016-10-04 Abbvie Inc comparações de amostras de proteínas
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EP2601609B1 (en) 2010-08-02 2017-05-17 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
CA2810909A1 (en) 2010-09-20 2012-03-29 Abbvie Inc. Purification of antibodies using simulated moving bed chromatography
US9005907B2 (en) 2010-10-01 2015-04-14 St. Jude Children's Research Hospital Methods and compositions for typing molecular subgroups of medulloblastoma
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
AU2011323784A1 (en) 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
SI2634194T1 (sl) 2010-10-29 2018-11-30 Perseus Proteomics Inc. Anti-cdh3 protitelo, ki ima visoko kapaciteto internalizacije
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
EP3202903B1 (en) 2010-12-22 2020-02-12 President and Fellows of Harvard College Continuous directed evolution
US20140038842A1 (en) 2010-12-28 2014-02-06 Xoma Technology Cell surface display using pdz domains
US9598499B2 (en) 2010-12-30 2017-03-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antigen binding formats for use in therapeutic treatments or diagnostic assays
SG192119A1 (en) 2011-01-24 2013-08-30 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
GB201103453D0 (en) 2011-03-01 2011-04-13 Vib Vzw Kinase substrate sensor
EP2680925B1 (en) 2011-03-02 2019-11-20 Berg LLC Interrogatory cell-based assays and uses thereof
CA2865487A1 (en) 2011-03-07 2012-09-13 Paula J. Bates Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
US9777332B2 (en) 2011-03-31 2017-10-03 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
CA2832565A1 (en) 2011-04-08 2012-10-11 Biogen Idec Ma Inc. Biomarkers predictive of therapeutic responsiveness to ifn.beta. and uses thereof
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
EP2700652B1 (en) 2011-04-18 2018-12-19 The University of Tokyo Diagnosis and treatment of cancer using anti-itm2a antibody
EP2703486B1 (en) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
BR112013030352B1 (pt) 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
KR102366029B1 (ko) 2011-09-30 2022-02-23 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
KR20250078601A (ko) 2011-09-30 2025-06-02 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN107287660A (zh) 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGENBINDING MOLECULE FOR PREPARING A SPACE BETWEEN A PLASMA AND AN ANTIGEN WITH A SACCHARIDE CHAIN RECEPTOR BINDING DOMAIN
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
EP3603671A3 (en) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
JP6301258B2 (ja) 2011-11-03 2018-03-28 トライパス イメージング インコーポレイテッド 免疫染色試料を調製するための方法および構成物
EP2773779B1 (en) 2011-11-04 2020-10-14 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
MX2014005570A (es) 2011-11-08 2014-05-30 Pfizer El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
BR112014011670B1 (pt) 2011-11-16 2021-05-25 Adrenomed Ag anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica
PL3553084T3 (pl) 2011-11-16 2023-04-17 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan
US9140696B2 (en) 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
ES2494190T3 (es) 2011-11-16 2014-09-15 Adrenomed Ag Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
HRP20191771T1 (hr) 2011-11-16 2019-12-27 Adrenomed Ag Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije
HRP20190122T1 (hr) 2011-11-16 2019-03-08 Adrenomed Ag Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US20140017174A1 (en) 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
CN104136462B (zh) 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
MX357708B (es) 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
WO2013131957A1 (en) 2012-03-06 2013-09-12 Vib Vzw Membrane span-kinase fusion protein and the uses thereof
WO2013148256A2 (en) * 2012-03-27 2013-10-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the generation of immunoglobulin sequences
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
JPWO2013147212A1 (ja) 2012-03-30 2015-12-14 第一三共株式会社 新規抗Ｓｉｇｌｅｃ−１５抗体
BR112014024537A2 (pt) 2012-04-02 2017-08-08 Berg Llc métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
AU2013247645B2 (en) 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
IN2014DN07799A (es) 2012-04-27 2015-05-15 Daiichi Sankyo Co Ltd
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
TW201348247A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
SG11201408330XA (en) 2012-05-24 2015-01-29 Mountgate Group Ltd Compositions and methods related to prevention and treatment of rabies infection
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US10444245B2 (en) 2012-05-24 2019-10-15 Vib Vzw Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins
JPWO2013180201A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
BR112014032916A2 (pt) 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
EP3613765B1 (en) 2012-08-03 2024-10-02 Dana-Farber Cancer Institute, Inc. Antibody against repulsive guidance molecule b (rgmb)
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
WO2014039860A2 (en) 2012-09-07 2014-03-13 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating dnmt1 inhibitor activity
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
MX2015004436A (es) 2012-10-09 2015-06-24 Biogen Idec Inc Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
DK2918603T3 (en) 2012-11-08 2018-10-15 Univ Miyazaki ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR
BR122020023058B1 (pt) 2012-12-10 2023-12-05 Biogen Ma Inc Ácido nucleico isolado ou ácidos nucleicos
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
CA2902789A1 (en) 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
MX362075B (es) 2013-03-14 2019-01-07 Abbott Lab Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
BR112015017307A2 (pt) 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
WO2014147153A1 (en) 2013-03-20 2014-09-25 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
CA2912526C (en) 2013-05-16 2021-09-14 Kyoto University Method for determining prognosis of cancer
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
EP3003372B1 (en) 2013-06-07 2019-10-09 Duke University Inhibitors of complement factor h
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
US20160159919A1 (en) 2013-06-24 2016-06-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding Adenocarcinoma
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
PL3036320T5 (pl) 2013-08-19 2024-06-10 Biogen Ma Inc. Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
WO2015034052A1 (ja) 2013-09-05 2015-03-12 国立大学法人 宮崎大学 ヒトインテグリンａ６ｂ４と特異的に反応する抗体
TWI673063B (zh) 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
EP3049521B1 (en) 2013-09-25 2019-03-06 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MX2016003617A (es) * 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
CA2925897A1 (en) 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
EP3470081A1 (en) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
CN105792844B (zh) 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
US20160272673A1 (en) 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of dvd-igs
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
EP2891722B1 (en) 2013-11-12 2018-10-10 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating endometriosis
KR102283408B1 (ko) 2013-11-15 2021-07-29 앵스티띠 파스퇴르 플라스모듐 팔시파룸 아르테미시닌 내성의 분자 마커
TWI702316B (zh) 2013-12-04 2020-08-21 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
US10654933B2 (en) 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子およびその使用
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
EP3116906A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
DK3122869T3 (da) 2014-03-24 2019-09-09 Biogen Ma Inc Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
CA2944456C (en) 2014-03-31 2023-10-31 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
WO2015150900A2 (en) 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
CA2956385A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
EP3185004A4 (en) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
CA2996445A1 (en) 2014-09-05 2016-03-10 Eli Hatchwell Methods and compositions for inhibiting and treating neurological conditions
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3200822B1 (en) 2014-09-30 2021-04-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to l1cam (cd171)
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
PL3215527T3 (pl) 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016144917A1 (en) 2015-03-10 2016-09-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
GB201504859D0 (en) 2015-03-23 2015-05-06 Vib Vzw Viral particle based small molecule-protein interaction trap
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
US10954515B2 (en) 2015-04-21 2021-03-23 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting ZNF555
CA2983293C (en) 2015-04-24 2023-06-20 The Regents Of The University Of California Modulators of ror1-ror2 binding
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
JP2018532693A (ja) 2015-08-06 2018-11-08 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
EP3341415B1 (en) 2015-08-28 2021-03-24 H. Hoffnabb-La Roche Ag Anti-hypusine antibodies and uses thereof
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3368157B1 (en) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
MX391162B (es) 2015-10-30 2025-03-21 Galaxy Biotech Llc Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
CA3007646A1 (en) 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
CN108697794A (zh) 2015-12-17 2018-10-23 诺华股份有限公司 C-met抑制剂和抗pd-1抗体分子的组合及其用途
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
WO2017113050A1 (zh) * 2015-12-28 2017-07-06 财团法人农业科技研究院 猪圆环病毒2型的外鞘蛋白质的制备方法及含该外鞘蛋白质的医药组合物
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
KR102611444B1 (ko) 2016-04-08 2023-12-06 지엘바이오, 인크. 플렉틴-1 결합 항체 및 그의 용도
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
IL262472B2 (en) 2016-04-21 2024-12-01 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitors for use in treating diseases related to necrosis
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
US11136405B2 (en) 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
EP3464371B1 (en) 2016-06-06 2026-07-29 City of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US11390661B2 (en) 2016-06-27 2022-07-19 Aicuris Anti-Infective Cures Gmbh HCMV entry inhibitors
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
CN109716136B (zh) 2016-07-08 2023-09-22 斯弗因高泰克有限公司 肾上腺髓质素用于评估急性心力衰竭患者的充血
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3484455A2 (en) 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
MA45715A (fr) 2016-07-25 2019-05-29 Biogen Ma Inc Anticorps anti-hspa5 (grp78) et leurs utilisations
CN118530358A (zh) 2016-08-01 2024-08-23 佐马美国有限公司 甲状旁腺激素受体1（pth1r）抗体和其用途
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
CA3036564A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
CA3036714A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
WO2018066626A1 (ja) 2016-10-07 2018-04-12 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する方法
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
KR20190120174A (ko) 2016-12-16 2019-10-23 아드레노메드 아게 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
CN118126180A (zh) 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
IL315727A (en) 2016-12-23 2024-11-01 Visterra Inc Binding polypeptides and methods for their preparation
CN110382530A (zh) 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
HRP20230308T1 (hr) 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
WO2018130661A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating brain conditions
CN110312530A (zh) 2017-01-13 2019-10-08 中央研究院 用以治疗心肌梗塞的可重复装载的水胶系统
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US11623945B2 (en) 2017-02-06 2023-04-11 The United States Of America, As Represented By The Secretary Of Agriculture Immunostimulating compositions and uses therefore
TW201837174A (zh) 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
EP3589650A1 (en) 2017-03-02 2020-01-08 Novartis AG Engineered heterodimeric proteins
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
EP3599843A4 (en) 2017-03-24 2021-01-13 The Regents of the University of California PROTEOGLYCAN IRREGULARITIES IN ABNORMAL FIBROBLASTS AND THERAPIES BASED ON THEM
EP3604340A4 (en) 2017-03-24 2021-01-06 Zenyaku Kogyo Co., Ltd ANTI-IGM / B-CELL SURFACE ANTIGEN-BISPECIFIC ANTIBODY
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
EP3609915A1 (en) 2017-04-12 2020-02-19 Pfizer Inc Antibodies having conditional affinity and methods of use thereof
EP3610268B1 (en) 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EP4328241A3 (en) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
ES3000510T3 (en) 2017-06-09 2025-02-28 Providence Health & Services Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3645042A4 (en) 2017-06-26 2021-03-17 Bio-Techne Corporation HYBRIDOMA CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND THEIR MANUFACTURING AND USE METHODS
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
US20200115446A1 (en) 2017-06-30 2020-04-16 National University Corporation Hokkaido University Pediatric osteoporosis drug that does not cause growth disorder
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
KR102787394B1 (ko) 2017-07-14 2025-03-26 화이자 인크. MAdCAM에 대한 항체
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
CA3071234A1 (en) 2017-07-27 2019-01-31 Daiichi Sankyo Company, Limited Anti-cd147 antibody
EP3658583A1 (en) 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US12060553B2 (en) 2017-08-25 2024-08-13 President And Fellows Of Harvard College Evolution of BoNT peptidases
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US20220227854A1 (en) 2017-09-25 2022-07-21 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
EP3461841B1 (en) 2017-10-02 2019-09-11 Certest Biotec, S.L. Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
AU2018344859A1 (en) 2017-10-04 2020-04-30 Hesperix SA Articles and methods directed to personalized therapy of cancer
BR112020006860A2 (pt) 2017-10-05 2020-10-20 Daiichi Sankyo Company, Limited composição para depleção de células t citotóxicas
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
MX2020004072A (es) 2017-10-18 2020-07-28 Adrenomed Ag Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
KR20200072507A (ko) 2017-10-19 2020-06-22 데비오팜 인터네셔날 에스 에이 암 치료를 위한 조합 제품
EP3697809A1 (en) 2017-10-20 2020-08-26 Institut Curie Dap10/12 based cars adapted for rush
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
KR102835427B1 (ko) 2017-10-25 2025-07-21 4틴4 파마슈티컬스 게엠베하 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
KR102717599B1 (ko) 2018-02-08 2024-10-14 스핑고텍 게엠베하 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제
EP3759125A4 (en) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. METHOD OF CANCER TREATMENT USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNCHECKPOINT BLOCKING REAGENTS
CN111836643A (zh) 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
KR20200131846A (ko) 2018-03-14 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 항-폴리시알산 항체 및 그 용도
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
DK3775909T3 (da) 2018-03-26 2023-07-24 Glycanostics S R O Midler og fremgangsmåder til glykoprofilering af et protein
MX2020010094A (es) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
JP7549530B2 (ja) 2018-05-21 2024-09-11 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
CA3104295A1 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
KR102891320B1 (ko) 2018-07-11 2025-11-28 스칼러 락, 인크. 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
ES3005559T3 (en) 2018-07-20 2025-03-14 Aicuris Anti Infective Cures Ag Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
FI4177356T3 (fi) 2018-08-08 2024-08-07 Pml Screening Llc Menetelmiä virustaudin kehittymisriskin arviointiin geenitestillä
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
KR20210068079A (ko) 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
IL281988B2 (en) 2018-10-05 2025-03-01 Bavarian Nordic As Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
MX2021004598A (es) 2018-10-23 2021-06-15 Scholar Rock Inc Inhibidores selectivos de rgmc y el uso de los mismos.
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CA3119956A1 (en) 2018-11-14 2020-05-22 Daiichi Sankyo Company, Limited Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
CN113164594A (zh) 2018-11-20 2021-07-23 株式会社英仙蛋白质科学 向细胞内摄入铁的抑制剂
JP7625518B2 (ja) 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
US20220211798A1 (en) 2018-12-21 2022-07-07 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
CA3127103A1 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
EP3696191A1 (en) 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
EP3932952A4 (en) 2019-02-28 2022-11-30 Juntendo Educational Foundation ANTIBODIES BINDING TO TRUNKED MUTANT CALRETICULIN AND DIAGNOSTIC, PROPHYLACTIC OR THERAPEUTIC DRUG FOR MYELOPROLIFERATIVE NEOPLASMA
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CA3133074A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
EP3938390A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
JP7601758B2 (ja) 2019-03-19 2024-12-17 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
BR112021017616A2 (pt) 2019-03-25 2021-11-09 Daiichi Sankyo Co Ltd Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND A PARP INHIBITOR
PH12021552414A1 (en) 2019-03-29 2022-07-25 Atarga Llc Anti fgf23 antibody
BR112021020204A2 (pt) 2019-04-10 2021-12-07 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo com região fc modificada
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
WO2020243021A2 (en) 2019-05-24 2020-12-03 Foundation Medicine, Inc. Ntrk fusion molecules and uses thereof
IL288485B2 (en) 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
US12594330B2 (en) 2019-06-04 2026-04-07 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN113905757B (zh) 2019-06-05 2026-01-13 中外制药株式会社 抗体切割位点结合分子
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
US12655182B2 (en) 2019-07-15 2026-06-16 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
EP4008350A4 (en) 2019-07-26 2023-06-14 Saitama Medical University ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
HUE064890T2 (hu) 2019-08-02 2024-04-28 Fundacio De Recerca Clinic Barcelona Inst BCMA elleni CAR T-sejtek mielóma multiplex kezelésére
EP4031658A1 (en) 2019-08-07 2022-07-27 DB Biotech, AS Improved horseradish peroxidase polypeptides
EP4021581A4 (en) 2019-08-30 2023-08-30 Foundation Medicine, Inc. Kmt2a-maml2 fusion molecules and uses thereof
WO2021038078A1 (en) 2019-08-30 2021-03-04 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
US20230220098A1 (en) 2019-09-04 2023-07-13 Perseus Proteomics Inc. Therapeutic drug for polycythemia
WO2021044009A1 (en) 2019-09-04 2021-03-11 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
CN114929743B (zh) 2019-09-05 2026-01-02 纪念斯隆凯特琳癌症中心 抗steap1抗体及其用途
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US20240148891A1 (en) 2019-10-18 2024-05-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
CN114630679A (zh) 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
BR112022009798A2 (pt) 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
WO2021107082A1 (ja) 2019-11-27 2021-06-03 株式会社ペルセウスプロテオミクス 癌性腹膜炎の治療薬
CA3162252A1 (en) 2019-12-17 2021-06-24 Nikolai Kley Modulation of protein degradation
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
JP7858532B2 (ja) 2020-01-10 2026-05-14 ダイン セラピューティクス，インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021150925A1 (en) 2020-01-24 2021-07-29 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
KR20220137698A (ko) 2020-02-05 2022-10-12 라리마 테라퓨틱스, 인코포레이티드 Tat 펩티드 결합 단백질 및 이의 용도
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CN115244401A (zh) 2020-02-27 2022-10-25 4Teen4制药有限公司 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
CN115244081A (zh) 2020-02-27 2022-10-25 艾德里诺医药公司 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂
EP4114979A4 (en) 2020-03-04 2025-08-27 Found Medicine Inc BCOR REDESIGNS AND THEIR USES
CA3174638A1 (en) 2020-03-11 2021-09-16 Fundacio Institut De Recerca Contra La Leucemia Josep Carreras Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
US20230213519A1 (en) 2020-03-16 2023-07-06 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
CN115335082A (zh) 2020-03-27 2022-11-11 光爱科技公司 用于杀死肿瘤细胞的医药品
CA3175577A1 (en) 2020-03-30 2021-10-07 Mie University Bispecific antibody
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
EP4134099A4 (en) 2020-04-06 2024-05-29 PhotoQ3 Inc. Medicine for killing tumor cells
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
CA3181949A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
CN115803062B (zh) 2020-06-03 2025-09-09 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
EP4174071A4 (en) 2020-06-24 2024-09-11 The University of Tokyo PHOTOSENSITIZING DYE
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
KR20230042273A (ko) 2020-06-24 2023-03-28 비스테라, 인크. April에 대한 항체 분자 및 그의 용도
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
AU2021308574A1 (en) 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
BR112023000216A2 (pt) 2020-07-28 2023-02-07 Chugai Pharmaceutical Co Ltd Preparação de seringa pré-carregada com agulha, com proteção de agulha e incluindo anticorpo modificado
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022024065A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
WO2022045247A1 (ja) 2020-08-27 2022-03-03 学校法人順天堂 抗切断型変異ｃａｌｒ－ｃｄ３二重特異性抗体及び医薬組成物
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022075439A1 (ja) 2020-10-08 2022-04-14 国立大学法人東海国立大学機構 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
MX2023004724A (es) 2020-10-23 2024-02-23 Hq Han Antagonistas bifuncionales de la activina y del factor alfa de necrosis tumoral y usos de los mismos.
US12704517B2 (en) 2020-11-24 2026-08-11 Bio-Techne Corporation Anti-severe acute respiratory syndrome coronavirus antibodies
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
MX2023007028A (es) 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
AU2021414227A1 (en) 2020-12-31 2023-07-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP4277665A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
WO2022159590A1 (en) 2021-01-20 2022-07-28 Visterra, Inc. Interleukin-2 mutants and uses thereof
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
US20240230671A9 (en) 2021-02-24 2024-07-11 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
WO2022187440A1 (en) 2021-03-03 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services La protien as a novel regulator of osteoclastogenesis
CN117320749A (zh) 2021-03-12 2023-12-29 中外制药株式会社 用于治疗或预防重症肌无力的药物组合物
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304991A (zh) 2021-03-29 2023-02-01 日商第一三共股份有限公司 穩定的多重特異性分子及其利用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
US12472248B2 (en) 2021-04-29 2025-11-18 The Government Of The United States, As Represented By The Secretary Of The Army Antibodies against fentanyl and fentanyl analogs
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20240277842A1 (en) 2021-06-07 2024-08-22 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
DK4358995T3 (da) 2021-06-23 2026-02-02 Scholar Rock Inc Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser
IL309345A (en) 2021-07-01 2024-02-01 Albert Einstein College Medicine Compositions and methods for inhibiting the expression of tmigd2
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
IL310535A (en) 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
KR20240049363A (ko) 2021-08-26 2024-04-16 가부시키가이샤 페르세우스 프로테오믹스 Ros(활성 산소종) 생산 증강제
AU2022335718A1 (en) 2021-08-26 2024-03-28 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
EP4144898A1 (de) 2021-09-07 2023-03-08 New/era/mabs GmbH Verfahren zur selektion oder screenen von antikörpern aus einer antikörperbibliothek
JP2024531711A (ja) 2021-09-14 2024-08-29 グリカノスティクス エス．アール．オー． 乳がんにおけるマンマグロビンａグリコフォームを測定するためのレクチンの使用法
US20240390512A1 (en) 2021-09-15 2024-11-28 Daiichi Sankyo Company, Limited Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
JP2024535888A (ja) 2021-09-20 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法
US20250000998A1 (en) 2021-09-24 2025-01-02 PhotoQ3 Inc. Medicament for killing tumor cells
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
EP4412583B1 (en) 2021-10-04 2026-07-08 Novartis AG Surfactant stabilizers
EP4413998A4 (en) 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION
EP4420683A1 (en) 2021-10-18 2024-08-28 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
CA3235627A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
JP7748680B2 (ja) 2021-11-16 2025-10-03 国立大学法人鳥取大学 改変ｄ領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023100829A1 (ja) 2021-11-30 2023-06-08 第一三共株式会社 プロテアーゼ分解性マスク抗体
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
KR20240011866A (ko) 2021-12-01 2024-01-26 추가이 세이야쿠 가부시키가이샤 항체 함유 제제의 조제 방법
JP2025503439A (ja) 2021-12-17 2025-02-04 アボット・ラボラトリーズ 血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
EP4472733A1 (en) 2022-01-31 2024-12-11 BYOMass Inc. Myeloproliferative conditions
JP2025507303A (ja) 2022-02-04 2025-03-18 アボット・ラボラトリーズ 試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
AU2023226293A1 (en) 2022-02-25 2024-09-05 Juntendo Educational Foundation Medicine comprising combination of anti-mutant-calr antibody and another drug
EP4490187A4 (en) 2022-03-08 2026-02-25 Immunedge Inc EPO RECEPTOR AGONISTS AND ANTAGONISTS
CN119072492A (zh) 2022-03-15 2024-12-03 艾德里诺医药公司 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂
WO2023176881A1 (ja) 2022-03-16 2023-09-21 第一三共株式会社 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
US20250263497A1 (en) 2022-04-19 2025-08-21 Tokai University Educational System Therapeutic agent for nk-cell tumor
AU2023262513A1 (en) 2022-04-25 2024-12-05 Visterra, Inc. Antibody molecules to april and uses thereof
KR20250005335A (ko) 2022-04-26 2025-01-09 추가이 세이야쿠 가부시키가이샤 의약 제제 함유 필터 내장 시린지
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN119255825A (zh) 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
EP4296279A1 (en) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
IL318667A (en) 2022-07-29 2025-03-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
US20260028423A1 (en) 2022-07-29 2026-01-29 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
CA3263767A1 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
CA3262904A1 (en) 2022-09-21 2024-03-28 Elthera Ag NEW BINDING MOLECULES THAT BIND TO L1CAM
EP4345109A1 (en) 2022-09-30 2024-04-03 AdrenoMed AG Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease
TW202426486A (zh) 2022-10-25 2024-07-01 日商第一三共股份有限公司 使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法
US20260201067A1 (en) 2022-12-15 2026-07-16 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
CN120548364A (zh) 2023-01-27 2025-08-26 第一三共株式会社 抗lrrc15抗体
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
EP4680966A1 (en) 2023-03-17 2026-01-21 PAM Theragnostics GmbH Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
JP2026513177A (ja) 2023-03-29 2026-04-23 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤
KR20250164708A (ko) 2023-03-29 2025-11-25 다이이찌 산쿄 가부시키가이샤 항 cd25 항체 및 항 cd25 항체-약물 콘주게이트
JP2026517628A (ja) 2023-04-04 2026-06-02 アボット・ラボラトリーズ 対象が亜急性後天性脳損傷（ａｂｉ）を負った、負った可能性がある、又は負っていると推測されるかどうかを決定するためのバイオマーカーの使用
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法
JPWO2024219442A1 (es) 2023-04-19 2024-10-24
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
CN121889677A (zh) 2023-09-25 2026-04-17 思芬构技术有限公司 用于肾移植患者中移植物功能降低的早期诊断、早期预测、监测或严重程度预测的方法
CN121941710A (zh) 2023-09-27 2026-04-28 艾尔瑟拉股份有限公司 用于治疗血液恶性肿瘤疾病的l1cam结合分子
JPWO2025105486A1 (es) 2023-11-17 2025-05-22
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AU2025206074A1 (en) 2024-01-03 2026-07-02 Kiniksa Pharmaceuticals, Gmbh Method of reducing aggregation in the virus-inactivated preparation of anti-cd40 antibodies
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
WO2025229075A1 (en) 2024-05-03 2025-11-06 Sphingotec Gmbh A method for the specific determination of proenkephalin fragment 119-159
WO2025235420A1 (en) 2024-05-06 2025-11-13 Generate Biomedicines, Inc. Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025235419A1 (en) 2024-05-06 2025-11-13 Generate Biomedicines, Inc. Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
EP4675277A1 (en) 2024-07-05 2026-01-07 Predemtec AG A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease
WO2026036047A1 (en) 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
WO2026037841A1 (en) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Anti-fgfr4 molecules and uses thereof
WO2026046947A1 (en) 2024-08-26 2026-03-05 4TEEN4 Pharmaceuticals GmbH Anti-dpp3 antibody directed to and binding to dpp3 for the treatment of shock in extreme-critically ill patients
WO2026046968A1 (en) 2024-08-26 2026-03-05 4TEEN4 Pharmaceuticals GmbH Dpp3 binders for the treatment of endothelial dysfunction
WO2026046982A1 (en) 2024-08-26 2026-03-05 Pam Theragnostics Gmbh A method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (iect)
WO2026046978A1 (en) 2024-08-26 2026-03-05 Pam Theragnostics Gmbh Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026055461A1 (en) 2024-09-05 2026-03-12 Aperture Therapeutics, Inc. Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026112563A1 (en) 2024-11-25 2026-05-28 Abbott Laboratories Systems and methods for tbi adjudication
WO2026136288A2 (en) 2024-12-18 2026-06-25 Generate Biomedicines, Inc. Antibodies or antigen-binding fragments thereof capable of binding to free drug and uses thereof
WO2026132786A1 (en) 2024-12-20 2026-06-25 Centessa Pharmaceuticals (Uk) Limited Anti-cd3 binding agents and uses thereof
WO2026148288A1 (en) 2025-01-06 2026-07-09 M2 Therapeutics, Inc. Antibodies and antigen-binding fragments thereof to growth hormone receptor and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006630A1 (en) * 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP0478627A4 (en) * 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance

Also Published As

Publication number Publication date
AU1693892A (en) 1992-12-30
CA2109602A1 (en) 1992-11-26
CA2109602C (en) 2002-10-01
AU665190B2 (en) 1995-12-21
DK0585287T3 (da) 2000-04-17
ATE185601T1 (de) 1999-10-15
GR3032186T3 (en) 2000-04-27
EP0585287B1 (en) 1999-10-13
JPH06508511A (ja) 1994-09-29
WO1992020791A1 (en) 1992-11-26
EP0585287A1 (en) 1994-03-09

Similar Documents

Publication Publication Date Title
GR3032186T3 (en) Methods for producing members of specific binding pairs
ES2096655T3 (es) Procedimiento para la produccion de fragmentos funcionales de anticuerpos fv de cadena simple en la superficie de particulas de bacteriofagos.
NO985467L (no) Antistoff og diagnostisk preparat omfattende dette
GB9206318D0 (en) Binding substances
DE69433090D1 (de) Conotoxine, die an den acetylcholinrezeptor anbinden
ES2249791T3 (es) Moleculas de adhesion de leucocitos a celulas endoteliales (elams) y moleculas involucradas en la adhesion de leucocitos (milas).
HUT58759A (en) Process for producing epidermis-specific growth factor, the dns coding this, the antibodys produced in them, and pharmaceutical compositions containing the growth factor or the antibody
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
DK0706569T3 (da) Medlemmer af specifikt bindende par med en kemisk tilbundet kovalent inden for bindingsstedet, fremstilling af udvælgelse a
ATE313633T1 (de) Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren
ES2061736T3 (es) Anticuerpos monoclonales contra interleucina-4 humana e hibridomas que los producen.
PT742821E (pt) Processo de preparacao de uma biblioteca multicombinatoria de vectores de expressao de genes de anticorpos
NO975714D0 (no) Fremgangsmåte for fremstilling av monoklonalt antistoff, monoklonalt antistoff og farmasöytisk blanding og diagnostisk reagens inneholdende samme
DE3686961D1 (de) Polydisperse native pseudomonas-flagella(h)-antigene (fag) und verfahren zu ihrer gewinnung.
DK0870050T3 (da) Virus, der udtrykker et toksisk protein, og producercellelinier
ATE110112T1 (de) Verfahren und systeme zur herstellung von hiv- antigenen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 585287

Country of ref document: ES